Contrasting GeneDx (NASDAQ:WGS) and Todos Med (OTCMKTS:TOMDF)

Todos Med (OTCMKTS:TOMDF) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Valuation and Earnings

This table compares Todos Med and GeneDx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Todos Med	N/A	N/A	N/A	N/A	N/A
GeneDx	$305.45 million	12.96	-$52.29 million	$0.09	1,521.72

Todos Med has higher earnings, but lower revenue than GeneDx.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Todos Med and GeneDx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Todos Med	0	0	0	0	0.00
GeneDx	1	3	7	0	2.55

GeneDx has a consensus price target of $135.89, suggesting a potential downside of 0.78%. Given Todos Med’s higher probable upside, equities analysts clearly believe Todos Med is more favorable than GeneDx.

Insider and Institutional Ownership

61.7% of GeneDx shares are held by institutional investors. 29.6% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Todos Med and GeneDx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Todos Med	N/A	N/A	N/A
GeneDx	0.52%	20.22%	11.89%

Volatility & Risk

Todos Med has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.

Summary

GeneDx beats Todos Med on 9 of the 10 factors compared between the two stocks.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.